Unity Biotechnology Stock Today

UBX Stock  USD 1.19  0.07  6.25%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 81

 
High
 
Low
Very High
Unity Biotechnology is trading at 1.19 as of the 7th of December 2024; that is 6.25 percent increase since the beginning of the trading day. The stock's open price was 1.12. Unity Biotechnology has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 14th of October 2023 and ending today, the 7th of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
3rd of May 2018
Category
Healthcare
Classification
Health Care
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. The company has 16.85 M outstanding shares of which 287.56 K shares are at this time shorted by investors with about 4.02 days to cover. More on Unity Biotechnology

Moving together with Unity Stock

  0.82MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.78OCX OncoCyte CorpPairCorr
  0.87PFE Pfizer Inc Fiscal Year End 4th of February 2025 PairCorr

Moving against Unity Stock

  0.77INFU InfuSystems HoldingsPairCorr
  0.75FUWAF Furukawa ElectricPairCorr
  0.7FMCB Farmers Merchants BancorpPairCorr
  0.66WAT WatersPairCorr
  0.43MOLN Molecular PartnersPairCorr

Unity Stock Highlights

Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00210.0022
Notably Down
Very volatile
Total Current Liabilities14.3 M7.8 M
Way Up
Slightly volatile
Non Current Liabilities Total33 M29.5 M
Moderately Up
Slightly volatile
Total Assets100.2 M65.7 M
Way Up
Pretty Stable
Total Current Assets81.9 M46.6 M
Way Up
Pretty Stable
Debt Levels
Unity Biotechnology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Unity Biotechnology's financial leverage. It provides some insight into what part of Unity Biotechnology's total assets is financed by creditors.
Liquidity
Unity Biotechnology has 26.99 M in debt with debt to equity (D/E) ratio of 1.3, which is OK given its current industry classification. Unity Biotechnology has a current ratio of 4.05, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Unity to invest in growth at high rates of return.

Depreciation

2.2 Million
Unity Biotechnology (UBX) is traded on NASDAQ Exchange in USA. It is located in 285 East Grand Avenue, South San Francisco, CA, United States, 94080 and employs 19 people. Unity Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 20.05 M. Unity Biotechnology runs under Biotechnology sector within Health Care industry. The entity has 16.85 M outstanding shares of which 287.56 K shares are at this time shorted by investors with about 4.02 days to cover. Unity Biotechnology has about 64.51 M in cash with (37.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Unity Biotechnology Probability Of Bankruptcy
Ownership Allocation
Unity Biotechnology shows a total of 16.85 Million outstanding shares. About 78.16 % of Unity Biotechnology outstanding shares are held by general public with 1.3 (%) owned by insiders and only 20.54 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Unity Ownership Details

Unity Stock Institutional Holders

InstituionRecorded OnShares
Morgan Stanley - Brokerage Accounts2024-09-30
44.7 K
Cercano Management Llc2024-09-30
41.2 K
State Street Corp2024-09-30
37.8 K
Bridgeway Capital Management, Llc2024-09-30
25 K
Commonwealth Equity Services Inc2024-06-30
24.6 K
Northern Trust Corp2024-09-30
22.5 K
Endowment Wealth Management, Inc.2024-09-30
13.5 K
Advisor Group Holdings, Inc.2024-06-30
13.1 K
Steward Partners Investment Advisory, Llc2024-06-30
3.5 K
Arch Venture Corp2024-09-30
M
Alyeska Investment Group, L.p.2024-09-30
920 K
View Unity Biotechnology Diagnostics

Unity Biotechnology Historical Income Statement

At this time, Unity Biotechnology's Interest Income is fairly stable compared to the past year. Depreciation And Amortization is likely to rise to about 1.5 M in 2024, despite the fact that Net Interest Income is likely to grow to (273.6 K). View More Fundamentals

Unity Stock Against Markets

Unity Biotechnology Corporate Management

Dr ABCoFounder DirectorProfile
Nathan GuzVice OperationsProfile
Judith CampisiFounderProfile
Daohong MDFounderProfile
Anirvan GhoshCEO DirectorProfile
Jamie MDChief OfficerProfile

Additional Tools for Unity Stock Analysis

When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.